|
Gene: ARID2 |
Gene summary for ARID2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARID2 | Gene ID | 196528 |
Gene name | AT-rich interaction domain 2 | |
Gene Alias | BAF200 | |
Cytomap | 12q12 | |
Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | Q68CP9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
196528 | ARID2 | CCI_1 | Human | Cervix | CC | 1.28e-09 | 7.48e-01 | 0.528 |
196528 | ARID2 | CCI_2 | Human | Cervix | CC | 7.81e-13 | 1.57e+00 | 0.5249 |
196528 | ARID2 | CCI_3 | Human | Cervix | CC | 4.37e-13 | 9.62e-01 | 0.516 |
196528 | ARID2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.57e-16 | -6.45e-01 | 0.0155 |
196528 | ARID2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.19e-02 | -4.54e-01 | -0.1207 |
196528 | ARID2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.73e-04 | -7.72e-01 | -0.2061 |
196528 | ARID2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 2.18e-02 | -6.02e-01 | -0.1462 |
196528 | ARID2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 6.15e-04 | -6.60e-01 | -0.0179 |
196528 | ARID2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.58e-13 | -5.35e-01 | 0.096 |
196528 | ARID2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.63e-04 | -4.50e-01 | 0.0338 |
196528 | ARID2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.43e-09 | -4.10e-01 | 0.0674 |
196528 | ARID2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.01e-07 | -3.58e-01 | 0.294 |
196528 | ARID2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.62e-02 | 7.36e-01 | 0.3487 |
196528 | ARID2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.30e-18 | -5.55e-01 | 0.3005 |
196528 | ARID2 | F007 | Human | Colorectum | FAP | 4.48e-02 | -2.25e-01 | 0.1176 |
196528 | ARID2 | A001-C-207 | Human | Colorectum | FAP | 1.46e-03 | -2.33e-01 | 0.1278 |
196528 | ARID2 | A015-C-203 | Human | Colorectum | FAP | 3.78e-34 | -5.22e-01 | -0.1294 |
196528 | ARID2 | A015-C-204 | Human | Colorectum | FAP | 1.89e-06 | -3.37e-01 | -0.0228 |
196528 | ARID2 | A014-C-040 | Human | Colorectum | FAP | 1.45e-04 | -2.68e-01 | -0.1184 |
196528 | ARID2 | A002-C-201 | Human | Colorectum | FAP | 2.71e-16 | -4.04e-01 | 0.0324 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003106021 | Oral cavity | NEOLP | regulation of histone methylation | 17/2005 | 69/18723 | 7.76e-04 | 6.23e-03 | 17 |
GO:00310622 | Oral cavity | NEOLP | positive regulation of histone methylation | 12/2005 | 41/18723 | 8.94e-04 | 7.02e-03 | 12 |
GO:00487383 | Oral cavity | NEOLP | cardiac muscle tissue development | 40/2005 | 236/18723 | 2.26e-03 | 1.47e-02 | 40 |
GO:00148551 | Oral cavity | NEOLP | striated muscle cell proliferation | 17/2005 | 76/18723 | 2.41e-03 | 1.54e-02 | 17 |
GO:00310572 | Oral cavity | NEOLP | negative regulation of histone modification | 12/2005 | 46/18723 | 2.66e-03 | 1.66e-02 | 12 |
GO:001802213 | Oral cavity | NEOLP | peptidyl-lysine methylation | 25/2005 | 131/18723 | 2.95e-03 | 1.81e-02 | 25 |
GO:200102221 | Oral cavity | NEOLP | positive regulation of response to DNA damage stimulus | 21/2005 | 105/18723 | 3.45e-03 | 2.05e-02 | 21 |
GO:0060038 | Oral cavity | NEOLP | cardiac muscle cell proliferation | 14/2005 | 60/18723 | 3.76e-03 | 2.17e-02 | 14 |
GO:00616473 | Oral cavity | NEOLP | histone H3-K9 modification | 12/2005 | 48/18723 | 3.89e-03 | 2.23e-02 | 12 |
GO:00515672 | Oral cavity | NEOLP | histone H3-K9 methylation | 10/2005 | 37/18723 | 4.48e-03 | 2.51e-02 | 10 |
GO:004863814 | Oral cavity | NEOLP | regulation of developmental growth | 51/2005 | 330/18723 | 4.64e-03 | 2.56e-02 | 51 |
GO:00064823 | Oral cavity | NEOLP | protein demethylation | 9/2005 | 33/18723 | 6.45e-03 | 3.32e-02 | 9 |
GO:00082143 | Oral cavity | NEOLP | protein dealkylation | 9/2005 | 33/18723 | 6.45e-03 | 3.32e-02 | 9 |
GO:003526511 | Oral cavity | NEOLP | organ growth | 30/2005 | 178/18723 | 8.07e-03 | 3.98e-02 | 30 |
GO:20007812 | Oral cavity | NEOLP | positive regulation of double-strand break repair | 10/2005 | 40/18723 | 8.10e-03 | 3.99e-02 | 10 |
GO:004873218 | Prostate | BPH | gland development | 122/3107 | 436/18723 | 1.13e-09 | 5.01e-08 | 122 |
GO:00165706 | Prostate | BPH | histone modification | 120/3107 | 463/18723 | 1.73e-07 | 3.89e-06 | 120 |
GO:00182055 | Prostate | BPH | peptidyl-lysine modification | 96/3107 | 376/18723 | 5.70e-06 | 8.39e-05 | 96 |
GO:00459265 | Prostate | BPH | negative regulation of growth | 68/3107 | 249/18723 | 1.26e-05 | 1.69e-04 | 68 |
GO:00605377 | Prostate | BPH | muscle tissue development | 100/3107 | 403/18723 | 1.35e-05 | 1.76e-04 | 100 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0522510 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa0522513 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa052252 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
hsa052253 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
hsa052254 | Colorectum | FAP | Hepatocellular carcinoma | 43/1404 | 168/8465 | 1.78e-03 | 8.99e-03 | 5.47e-03 | 43 |
hsa052255 | Colorectum | FAP | Hepatocellular carcinoma | 43/1404 | 168/8465 | 1.78e-03 | 8.99e-03 | 5.47e-03 | 43 |
hsa052256 | Colorectum | CRC | Hepatocellular carcinoma | 37/1091 | 168/8465 | 6.38e-04 | 5.89e-03 | 3.99e-03 | 37 |
hsa052257 | Colorectum | CRC | Hepatocellular carcinoma | 37/1091 | 168/8465 | 6.38e-04 | 5.89e-03 | 3.99e-03 | 37 |
hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa052259 | Lung | IAC | Hepatocellular carcinoma | 33/1053 | 168/8465 | 4.77e-03 | 2.15e-02 | 1.43e-02 | 33 |
hsa0522512 | Lung | IAC | Hepatocellular carcinoma | 33/1053 | 168/8465 | 4.77e-03 | 2.15e-02 | 1.43e-02 | 33 |
hsa0522521 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
hsa0522531 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
hsa0522516 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
hsa0522517 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
hsa0522523 | Oral cavity | EOLP | Hepatocellular carcinoma | 39/1218 | 168/8465 | 1.35e-03 | 4.80e-03 | 2.83e-03 | 39 |
hsa0522533 | Oral cavity | EOLP | Hepatocellular carcinoma | 39/1218 | 168/8465 | 1.35e-03 | 4.80e-03 | 2.83e-03 | 39 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARID2 | SNV | Missense_Mutation | c.3931N>G | p.Lys1311Glu | p.K1311E | Q68CP9 | protein_coding | tolerated_low_confidence(0.06) | benign(0.444) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD | |
ARID2 | SNV | Missense_Mutation | c.4304C>T | p.Ser1435Leu | p.S1435L | Q68CP9 | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
ARID2 | SNV | Missense_Mutation | c.1113N>C | p.Lys371Asn | p.K371N | Q68CP9 | protein_coding | tolerated(0.08) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ARID2 | SNV | Missense_Mutation | novel | c.3877N>A | p.Leu1293Ile | p.L1293I | Q68CP9 | protein_coding | tolerated_low_confidence(0.08) | benign(0.019) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARID2 | SNV | Missense_Mutation | c.5199T>G | p.Ile1733Met | p.I1733M | Q68CP9 | protein_coding | deleterious(0.01) | benign(0.294) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ARID2 | SNV | Missense_Mutation | c.4364N>A | p.Ser1455Asn | p.S1455N | Q68CP9 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
ARID2 | SNV | Missense_Mutation | c.1715N>A | p.Arg572Lys | p.R572K | Q68CP9 | protein_coding | tolerated(0.1) | probably_damaging(0.987) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ARID2 | SNV | Missense_Mutation | c.4531N>A | p.Glu1511Lys | p.E1511K | Q68CP9 | protein_coding | deleterious_low_confidence(0) | benign(0.257) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ARID2 | SNV | Missense_Mutation | c.2713C>A | p.Gln905Lys | p.Q905K | Q68CP9 | protein_coding | tolerated_low_confidence(0.38) | benign(0.01) | TCGA-BH-A18N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARID2 | SNV | Missense_Mutation | novel | c.4758N>T | p.Gln1586His | p.Q1586H | Q68CP9 | protein_coding | deleterious(0.02) | possibly_damaging(0.564) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |